Universal Diagnostics S.A.

Over the past few months, ICEX – Invest in Spain released the 2025 Starting Up in Spain: Startup Ecosystem Overview & Soft-Landing Guide, and we’re proud to share that Universal Diagnostics S.A. is featured among Spain’s top scaleups. The report showcases the impressive momentum of Spain’s innovation landscape: 📈 The Spanish tech ecosystem reached a €112.7 billion valuation by the end of 2024, growing more than 4.5× since 2018 💸 In 2024 alone, over €3 billion was invested in Spanish startups and scaleups, with 70–80% of it coming from international VCs A big thank you to ICEX for spotlighting the ecosystem and to our amazing UDX team for making this recognition possible. We're proud to contribute to Spain’s growing global footprint in biotech and diagnostics. 📚 Read the full ICEX guide: https://lnkd.in/ddGyqAY9 #UniversalDX

🎯 UDX is back from American Association for Cancer Research Annual Meeting 2025 – and proud to share our scientific contributions! Our team has presented two research posters at the American Association for Cancer Research (AACR) Annual Meeting in Chicago: -DNA Methylation Profiles Classify Dysplasia Degree in Colorectal Adenomas: We identified a robust methylation signature distinguishing low- vs. high-grade dysplasia in both tissue and plasma — paving the way for early, non-invasive risk stratification. -Multiomics Signature Reveals Network Regulatory Mechanisms in Colorectal Cancer Progression: Using multiomics integration, we uncovered transcription factor–driven regulatory networks linked to CRC progression, subtypes, and survival. 👥 Many thanks to our authors Juan Carlos H., Francesco Mattia Mancuso, Pol Canal Noguer, Kristi Kruusmaa, and Arianna Bertossi, as well as the rest of the team representing UDX at the congress: Vivian Erklavec Zajec, Arne Gouwy and Miklós Gábriel Tulics, PhD. We're thrilled to contribute to the global conversation on advancing colorectal cancer diagnostics and proud of our team’s continued commitment to innovation. #AACR25 #CancerResearch #Multiomics #Methylation #ColorectalCancer #EarlyDetection #UniversalDX

Universal Diagnostics S.A. announces a €20 million financing from the European Investment Bank (EIB) to support the development and commercialization of our cutting-edge blood-based liquid biopsy solutions for early cancer detection. This financing, backed by the #InvestEU program, will accelerate the expansion of our most advanced product, Signal-C® for colorectal cancer screening, as well as the development of Signal-Li and Signal-Lu for liver and lung cancer, respectively. It will also support our U.S. clinical trial for FDA approval and reimbursement, bringing us closer to offering a non-invasive, highly accurate cancer screening solution. At Universal DX, our mission is to transform cancer into a curable disease by detecting it early. Our proprietary technology, which combines next-generation sequencing, methylation, fragmentation, and microbiome biomarkers with AI-driven bioinformatics, is at the forefront of innovation in the MedTech space. “With the transformative power of our technology, we are taking bold steps toward our vision of making cancer a curable disease. The support from the EIB will enable us to bring our revolutionary blood tests to both European and U.S. markets.” – Juan Martinez-Barea, Founder and Chairman of Universal DX This funding also contributes to Europe’s Beating Cancer Plan, reinforcing the EIB’s commitment to technological innovation in healthcare. #CancerDetection #LiquidBiopsy #EIB #InvestEU

We are pleased to announce that our latest research, "Colorectal Adenoma Subtypes Exhibit Signature Molecular Profiles: Unique Insights into the Microenvironment of Advanced Precancerous Lesions for Early Detection Applications," has been accepted and published in Cancers MDPI as part of their Special Issue "Emerging Therapies in the Management of Gastrointestinal Malignancies." 🔬 This study provides a deep dive into the molecular landscape of colorectal #adenoma subtypes, revealing distinct DNA methylation patterns, copy number variations, and genetic mutations. These insights offer valuable opportunities to enhance early detection and prevention strategies for colorectal cancer. 📖 Read the full article: https://lnkd.in/dS2z4ZUT Thank you to our incredible research team Francesco Mattia Mancuso, Juan Carlos H., Pol Canal Noguer, Arianna Bertossi, Alexandre Perera LLuna from Universitat Politècnica de Catalunya (UPC), Michael Herbert Alexander Roehrl from Beth Israel Deaconess Medical Center & Kristi Kruusmaa for their dedication and expertise. At Universal Diagnostics S.A., we remain committed to pioneering innovative approaches for the early detection of cancer. #ColorectalCancer #EarlyDetection

Thrilled to be a part of #aacrLBx24 and excited to showcase our collaboration with Universal Diagnostics S.A. in developing an innovative early-detection workflow for colorectal cancer. #Epigenomics #BiomarkerDiscovery #LiquidBiopsy

Universal Diagnostics S.A. has been featured in Startup to Follow for our revolutionary approach to colorectal cancer screening. 🧬 Signal-C, our cutting-edge blood-based test, is transforming early detection, providing a non-invasive and highly accurate solution. Check out the full article below. Thank you to Startup to Follow. #ColorectalCancer #EarlyDetection #InnovationInHealthcare #SignalC #MedTech #HealthcareTransformation